0001642375
false
0001642375
2023-07-25
2023-07-25
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or Section 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): July 25, 2023
GUARDION
HEALTH SCIENCES, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-38861 |
|
47-4428421 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(I.R.S.
Employer
Identification
No.) |
2925
Richmond Avenue, Suite 1200
Houston,
Texas 77098
(Address
of principal executive offices, including zip code)
Registrant’s
telephone number, including area code: (800) 873-5141
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
Common
Stock, par value $0.001 per share |
|
GHSI |
|
The
Nasdaq Stock Market LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item
5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of
Certain Officers.
Appointment
of Chief Accounting Officer
On
July 25, 2023, the Board of Directors of Guardion Health Sciences, Inc. (the “Company”) approved the appointment of Katie
Cox as Chief Accounting Officer of the Company at an annual base salary of $225,000 (the “Base Salary”). Ms. Cox will also
be eligible to participate in the Company’s benefit programs as may be offered from time to time to other similarly situated employees.
Her appointment became effective July 25, 2023.
Prior
to her appointment as Chief Accounting Officer, Ms. Cox served as the Company’s Head of Financial Planning and Analysis since
June 2022. On May 18, 2023, Ms. Cox entered into a Retention Agreement with the Company (the “Retention Agreement”),
pursuant to which Ms. Cox will be entitled to receive a bonus of $50,000, which will be paid to Ms. Cox within 30 days immediately
following a Change of Control Transaction (as such term is defined in the Retention Agreement). In addition, and subject to the
satisfaction of certain conditions set forth in the Retention Agreement, in the event that a Change of Control Transaction is not
consummated prior to December 31, 2023, Ms. Cox will be eligible to receive a retention bonus of $50,000, which if not otherwise
forfeited, will be paid on December 31, 2023. Pursuant to the Retention Agreement, in the event that the Company terminates Ms.
Cox’s employment without Cause (as such term is defined in the Retention Agreement), the Company shall continue to pay her
Base Salary for a period of 6 months thereafter.
Prior
to joining the Company, Ms. Cox served as Director of Financial Planning and Analysis of Catalent Pharma Solutions, a subsidiary of Catalent,
Inc. (NYSE: CTLT) from September 2019 through June 2022. From September 2009 through September 2019, Ms. Cox served as Finance Manager
of Baxter Pharmaceutical Solutions, LLC, a subsidiary of Baxter International (NYSE: BAX). Ms. Cox holds a BA in Psychology from Indiana
University and an MBA from Indiana Wesleyan University.
There
are no arrangements between Ms. Cox and any other persons pursuant to which she was appointed to serve as the Company’s Chief Accounting
Officer. There are no family relationships between Ms. Cox and any director or executive officer of the Company, and she has no direct
or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K.
Departure
of Chief Accounting Officer
On
July 25, 2023, Jeffrey Benjamin, the Chief Accounting Officer and the Principal Financial Officer of the Company, provided the Company
with notice that he was resigning from his position as Chief Accounting Officer, which became effective July 25, 2023, and as an employee
of the Company effective August 4, 2023.
Item
9.01 Financial Statements and Exhibits
(d)
Exhibits.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
GUARDION
HEALTH SCIENCES, INC. |
Date:
July 31, 2023 |
|
|
|
By: |
/s/
Jan Hall |
|
Name: |
Jan
Hall |
|
Title: |
President
and Chief Executive Officer |
Exhibit
10.1
May
18, 2023
Katherine
Cox
13777
Tender Drive
Carmel,
IN 46032
Re:
Retention Agreement
Dear
Katie:
Guardion
Health Sciences, Inc. (the “Company”) wishes to recognize and reward your contributions to our success and
to encourage your active involvement and continued contributions to the Company. Therefore, the Company is pleased to offer you this
Retention Agreement (the “Agreement”), which, when signed by you and returned to me, will provide you financial
incentives to maintain the growth of the Company’s revenue and actively facilitate a Change of Control Transaction (and to work
toward closing a Change of Control Transaction prior to December 31, 2023). Any capitalized terms have the meaning set forth herein.
The
terms of this Agreement are as follows:
1.
Incentive Bonus. Subject to the terms and conditions of this Agreement, including, but not limited to, satisfying the eligibility
requirements set forth in Section 2 below, if a Change of Control Transaction is consummated on or before December 31, 2023, you
will become eligible to receive a bonus of $50,000 (the “Transaction Bonus”), which amount, if not otherwise
forfeited, will be paid to you within thirty (30) days immediately following the consummation of the Change of Control Transaction. In
the event a Change of Control Transaction is not consummated by the Company on or before December 31, 2023 or you do not otherwise meet
the eligibility requirements below, you will forfeit your right to receive, and the Company shall have no obligation to pay you, a Transaction
Bonus under this Agreement. Notwithstanding the foregoing, subject to the terms and conditions of this Agreement, including, but not
limited to, satisfying the eligibility requirements set forth in Section 2 below, in the event a Change of Control Transaction
is not consummated by December 31, 2023, you will be eligible to receive a retention bonus of $50,000 (the “Retention
Bonus” and, when referring to both the Retention Bonus and Transaction Bonus, the “Incentive Bonus”),
which amount if not otherwise forfeited will be paid to you on December 31, 2023. In the event that a Change of Control Transaction is
consummated prior to December 31, 2023 or you do not otherwise meet the eligibility requirements for a Retention Bonus, you will forfeit
your right to receive, and the Company shall have no obligation to pay you, a Retention Bonus under this Agreement. In no event will
you be eligible to receive both a Transaction Bonus and a Retention Bonus.
2.
Eligibility and Vesting Requirements.
(a)
To receive the Incentive Bonus, you must (i) be a full-time employee of the Company or any of its affiliates in good standing; (ii) have
fulfilled all of your commitments under this Agreement and your commitments set forth in Sections 3, 5 and Section 6 below (as
determined in the reasonable discretion of the Company) as of the closing date of a Change of Control Transaction, and (iii) be employed
on the payment date applicable to your Incentive Bonus.
(b)
In connection with any Change of Control Transaction, as a condition to receiving your Transaction Bonus under this Agreement, you will,
if requested by the Company, execute and deliver to the Company and/or any subsidiaries of the Company (the “Covered Parties”)
or acquirer (as applicable) (A) a Release of the Covered Parties in a form prescribed by the Company, for acts, omissions or occurrences
of the Company prior to such Change of Control Transaction, including those arising under this Agreement and (B) any offer letter or
employment, retention or other agreement (which agreement may include nondisclosure, nonsolicitation, noncompetition, intellectual property
rights or other restrictive covenants, or representations as to your knowledge regarding the Covered Parties or their business(es)),
requested by the Company and/or an acquirer in connection with such Change of Control Transaction. You will be granted a reasonable opportunity
to negotiate the terms of any such document or agreement; however, in order to receive the payment, you must execute, deliver, and not
revoke the Release and enter into any such document or agreement in the form as ultimately required by the Company and/or an acquirer
(subject to this paragraph) prior to the closing date of the Change of Control Transaction.
(c)
Forfeiture.
i.
You will forfeit your Incentive Bonus, including rights to receive any payment (i.e., past or future) with respect thereto, upon your
violation of any confidentiality, noncompetition, nonsolicitation, intellectual property rights or nondisclosure covenant set forth in
any written agreement between you and the Company. For clarity, you will forfeit any right to an Incentive Bonus upon termination of
your continuous service for any reason. Notwithstanding anything in this Section 2, the Board may, in its sole discretion, waive
the forfeiture of any or all your Incentive Bonus upon your termination of continuous service or other forfeiture trigger set forth herein.
Any such waiver must be in writing, explicitly reference this Section 2(c) and such waiver of a forfeiture requirement is permissible
under Code Section 409A in all respects.
ii.
If you violate any of the covenants or agreements set forth in this Agreement or any other material agreement with the Company, then
you will not be eligible to receive the Incentive Bonus and, in addition, the Company will be entitled to exercise all remedies available
under law or equity, including injunctive relief, and damages.
3.
Your Commitments. In consideration for the opportunity to earn the Incentive Bonus described in this Agreement, you agree to the
following:
(a)
During your period of employment with the Company and its affiliates, you will devote your full working time, talents, and energy to
the performance of your duties for the Company and will exert your best efforts to contribute to the financial success of the Company
and its affiliates.
(b)
During your period of employment with the Company and its affiliates, you will not engage in any conduct that is competitive with or
otherwise harmful to the Company’s business.
(c)
During your period of employment with the Company and its affiliates, you will comply with the lawful policies or agreements of the Company
and its affiliates in all material respects (or in all respects upon notice of a violation thereof).
(d)
You acknowledge and agree that the obligations imposed on you by this Agreement are in addition to, and not in lieu of, any and all other
policies of or agreements with the Company or its affiliates.
4.
Severance. In the event that the Company terminates your employment without Cause, including if your employment is terminated following
a Change of Control Transaction, subject to you executing a not revoking a Release in such form as provided by the Company (or its successor),
the Company shall continue to pay you six (6) months of your base salary (“Severance”), in addition to any
base salary earned through your termination date, subject to the Company’s reimbursement policy, reimbursement for business expenses
incurred prior to your termination date, and, subject to the terms of the applicable benefit plan, any vested benefits accrued under
a Company benefit plan. Your Severance shall be paid in accordance with the Company’s normal payroll practices with the first payment
commencing within thirty (30) days following your termination date (provide is such thirty (30) day period spans two calendar years,
the first payment of Severance shall be made in the second calendar year).
5.
Confidentiality. In consideration for the payments and agreements described in this Agreement, you agree that, except as required
in the performance of your duties on behalf of the Company or its affiliates, or to the extent otherwise required by law, you will not
disclose to any party information related to the existence and/or contents of this Agreement, or information relating to the existence
or terms of any Change of Control Transaction including, without limitation, price, parties, arrangements, schedules and all related
information pertinent to the solicitation, presentation and closure of the Change of Control Transaction, or the fact that the Company
would consider a future Change of Control Transaction. However, you may disclose the terms of this Agreement to your spouse or to your
legal or financial adviser, provided that you take all reasonable measures to assure that they do not disclose the terms of this Agreement
to another third party except as otherwise required by law.
6.
Return of Property; Intellectual Property Rights. In consideration for the payments and agreements described in this Agreement, you
agree that on or before your termination of employment for any reason with the Company and its affiliates, you will return all property
owned by the Company or its affiliates, including files, documents, data and records (whether on paper, tapes, disks, or in any other
form, electronic or otherwise), office equipment, credit cards, and employee identification cards. You acknowledge that the Company or
its affiliates is the rightful owner of any programs, ideas, inventions, discoveries, improvements and enhancements, works of authorship,
trade secrets or trademarks, including without limitation Internet domain names or other intellectual property, which you may have originated
or developed, or assisted in originating or developing, during your period of employment with the Company and its affiliates, where any
such origination or development involved the use of Company or its affiliates’ time or resources, or the exercise of your responsibilities
for or on behalf of the Company or its affiliates. You will at all times, both before and after termination of employment, cooperate
with the Company and its affiliates in executing and delivering documents and taking any other actions that are necessary or requested
by the Company or its affiliates to assist the Company or its affiliates in patenting, copyrighting or registering any programs, ideas,
inventions, discoveries, works of authorship, trademarks or such other intellectual property, to vest title thereto in the Company or
its affiliates, and to maintain Company’s or its affiliates’ rights therein.
7.
Definitions. For purposes of this Agreement, the following terms will have the meanings set forth below:
(a)
“Beneficial Owner” (or any variant thereof) has the meaning defined in Rule 13d-3 under the Exchange Act.
(b)
“Board” means the Board of Directors of the Company.
(c)
“Cause” means the occurrence of any of the following, as determined in good faith by the Company: (1) your
conviction of or plea of guilty or nolo contendere to a felony, or any other crime involving moral turpitude or which results in material
harm to the Company, (2) any act or omission involving fraud against the Company or any breach of fiduciary duty owed to the Company,
(3) your theft, misappropriation or embezzlement of the assets or funds of the Company or any customer, or engagement in misconduct that
is materially injurious to the Company, (4) any act or omission by you involving your gross negligence or willful misconduct in the performance
of your duties, (5) your material breach of any restrictive covenants set forth in a written agreement between you and the Company, or
an affiliate of the Company, or a material breach of any Company policies, which breach or violation, if capable of being cured, is not
cured to the Company’s reasonable satisfaction within ten (10) business days after you receive written notice thereof; (6) your
continuous failure to perform your assigned duties or responsibilities if such failure is not cured to the Company’s reasonable
satisfaction within ten (10) business days after you receive written notice thereof; or (7) your knowing violation of any federal or
state law or regulation applicable to the Company’s business.
(d)
“Change of Control Transaction” means the first occurrence of an event set forth below:
i.
any Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities
Beneficially Owned by such Person which were acquired directly from the Company or any affiliate thereof) representing more than fifty
percent (50%) of the combined voting power of the Company’s then outstanding securities, excluding any Person who becomes such
a Beneficial Owner in connection with a transaction described in clause (A) of paragraph (iii) below; or
ii.
the date on which individuals who constitute the Board as of the date of this Agreement and any new director (other than a director whose
initial assumption of office is in connection with an actual or threatened election contest, including, but not limited to, a consent
solicitation, relating to the election of directors of the Company) whose appointment or election by the Board or nomination for election
by the Company’s stockholders was approved or recommended by a vote of at least two-thirds (2/3) of the directors then still in
office who either were directors on the date of this Agreement or whose appointment, election or nomination for election was previously
so approved or recommended cease for any reason to constitute a majority of the number of directors serving on the Board; or
iii.
there is consummated a merger or consolidation of the Company or any direct or indirect subsidiary with any other corporation or other
entity, other than (A) a merger or consolidation (x) which results in the voting securities of the Company outstanding immediately prior
to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities
of the surviving entity or any parent thereof), in combination with the ownership of any trustee or other fiduciary holding securities
under an employee benefit plan of the Company or any subsidiary, fifty percent (50%) or more of the combined voting power of the securities
of the Company or such surviving entity or any parent thereof outstanding immediately after such merger or consolidation and (y) following
which the individuals who comprise the Board immediately prior thereto constitute at least a majority of the Board, the entity surviving
such merger or consolidation or, if the Company or the entity surviving such merger or consolidation is then a subsidiary, the ultimate
parent thereof, or (B) a merger or consolidation effected to implement a recapitalization of the Company (or similar transaction) in
which no Person is or becomes the Beneficial Owner, directly or indirectly, of securities of the Company (not including in the securities
Beneficially Owned by such Person any securities acquired directly from the Company or its affiliates) representing more than fifty percent
(50%) of the combined voting power of the Company’s then outstanding securities; or
iv.
the stockholders of the Company approve a plan of complete liquidation or dissolution of the Company or there is consummated an agreement
for the sale or disposition by the Company of all or substantially all of the Company’s assets, other than (A) a sale or disposition
by the Company of all or substantially all of the Company’s assets to an entity, more than fifty percent (50%) of the combined
voting power of the voting securities of which are owned by stockholders of the Company following the completion of such transaction
in substantially the same proportions as their ownership of the Company immediately prior to such sale or (B) a sale or disposition of
all or substantially all of the Company’s assets immediately following which the individuals who comprise the Board immediately
prior thereto constitute at least a majority of the board of directors of the entity to which such assets are sold or disposed or, if
such entity is a subsidiary, the ultimate parent thereof. Notwithstanding the foregoing, and for clarity, a sale of Viactiv line of products
will constitute a sale of substantially all of the assets of the Company and a Change of Control Transaction.
Notwithstanding
the foregoing, a Change of Control Transaction shall not be deemed to have occurred by virtue of the consummation of any transaction
or series of integrated transactions immediately following which the holders of the Common Stock immediately prior to such transaction
or series of transactions continue to have substantially the same proportionate ownership in an entity which owns all or substantially
all of the assets of the Company immediately following such transaction or series of transactions.
(e)
“Code” means the Internal Revenue Code of 1986, as amended.
(f)
“Common Stock” means the common stock of the Company, having a par value of $0.0001 per share.
(g)
“Person” means any individual person, firm, partnership, association, corporation, limited liability
company, or other business organization, entity or enterprise; provided, however, “Person” shall not include (i) the
Company or any subsidiary thereof, (ii) a trustee or other fiduciary holding securities under an employee benefit plan of the
Company or any subsidiary thereof, (iii) an underwriter temporarily holding securities pursuant to an offering of such securities,
or (iv) a corporation owned, directly or indirectly, by the stockholders of the Company in substantially the same proportions as
their ownership of shares of the Company.
(h)
“Release” means a general release of all claims that the you have or may have against the Company, its Board,
any of its subsidiaries or affiliates, or any of its employees, directors, officers, employees, agents, plan sponsors, administrators,
successors, fiduciaries, or attorneys, arising out of your employment with, and termination of employment from, the Company, except for
any claims to enforce the terms of this Agreement and the then-applicable terms of any other written agreement, plan or arrangement of
the Company or any of its subsidiaries or affiliates, and any claims for unemployment or workers’ compensation benefits by you.
8.
Other Material Terms.
(a)
Negotiation of a Change of Control Transaction. It is agreed and understood that at all times the Company will have the right
to approve or disapprove of any prospective acquirer or investor, or the terms and conditions of any proposed Change of Control Transaction,
and that the Company will have no obligation to enter into any Change of Control Transaction.
(b)
Discharge of Obligations. Any payment made by the Company in good faith in accordance with the provisions of this Agreement shall
fully discharge the Company from all further obligations with respect to such payment and this Agreement and in no event will you be
entitled to receive both a Transaction Bonus and a Retention Bonus. The Company may require that a condition to your receipt of your
Incentive Bonus be your execution and delivery of documents as the Company shall require, as well as a Release in form and substance
reasonably required by the Company.
(c)
Offset for Amounts Owed by You. If at any time when payments are to be made in accordance with the terms and conditions of this
Agreement, you are indebted to or otherwise owe money to the Company or its affiliates, then the payments to be made to you may, at the
Company’s discretion, be reduced by the amount of such indebtedness or other amount owed. An election by the Company not to reduce
such payments shall not constitute a waiver by the Company or affiliate of its claim for such repayment to the extent permissible under
Code Section 409A.
(d)
Golden Parachute Limitation. The Company intends that the benefits provided under this Plan will not constitute an “excess
parachute payment” under Code Section 280G. Notwithstanding any provision of this Agreement to the contrary, if any benefit to
be paid under this Agreement (together with any benefit to be paid to you under any other agreement, plan or arrangement) would be an
excess parachute payment, but for the application of this sentence, then the payments and benefits to be paid or provided under this
Agreement shall be reduced to the minimum extent necessary (but in no event less than zero) so that no portion of any such payment or
benefit, as so reduced, constitutes an excess parachute payment.
9.
Miscellaneous.
(a)
Assignment. The Company may assign any or all of its rights and obligations under this Agreement to any successor or affiliate
of the Company, if such successor or affiliate agrees to assume all the obligations of the Company hereunder. You hereby consent to any
such assignment and assumption. Your rights and obligations under this Agreement are not transferrable other than by will or the laws
of descent and distribution, and may be realized during your lifetime only by you or your guardian or legal representative.
(b)
Taxes. The Company may withhold from any amounts payable under this Agreement all taxes that the Company reasonably determines
to be required pursuant to any law, regulation, or ruling. However, it is your obligation to pay all required taxes on any amounts provided
under this Agreement, regardless of whether withholding is required. Notwithstanding any other provision of this Agreement, the Company
does not make any guarantee of tax consequences with respect to this Agreement or any benefits or payments provided for herein.
(c)
409A Compliance. It is intended that any amounts payable under this Agreement shall comply with the provisions of Code Section
409A and the Treasury regulations relating thereto including, without limitation, the provisions and requirements of Treasury Regulations
Section 1.409A-3(i)(5)(iv), so as not to subject you to the payment of any interest or tax penalty that may be imposed under Code Section
409A. Further, for purposes of the limitations on nonqualified deferred compensation under Code Section 409A, each payment of compensation
under this Agreement shall be treated as a separate payment of compensation for purposes of applying the exclusion for short-term deferral
amounts. In furtherance of this interest, to the extent that any regulations or other guidance issued under Code Section 409A after the
date of this Agreement would result in payment of interest or tax penalty under Code Section 409A, the Company and you agree to amend
this Agreement in order to bring this Agreement into compliance with the exemption provisions of Code Section 409A. In no event shall
the Company, its affiliates, successors, shareholders, employees, officers or agents have any liability relating to the failure or alleged
failure of any payment or benefit under this Agreement to comply with, or be exempt from, the requirements of Section 409A.
(d)
Entire Agreement; Modification. This Agreement sets forth the entire understanding of you and the Company regarding payment of
any severance, transaction bonus, retention bonus or other change of control bonus amounts, and supersedes all prior oral or written
agreements between you and the Company regarding the payment of any such amounts. Nothing in this Agreement shall supersede or otherwise
negate any post-employment confidentiality, nondisclosure, nonsolicitation, noninterference, intellectual property or noncompetition
obligations imposed by any other agreement between you and any of the Covered Parties. This Agreement may not be modified except by written
agreement by you and the Company.
(e)
Notices. All correspondences by the parties pursuant to this Agreement will be provided to the other party at the address listed
on the first page of this Agreement, or as otherwise supplemented by a party hereto pursuant to notice.
(f)
General Creditor Status. The Company’s obligations under this Agreement shall be unsecured and unfunded obligations, and
you shall be a general creditor of the Company.
(g)
Third Party Beneficiaries. The terms and provisions of this Agreement are intended solely for you, the Company and its affiliates,
and each of their respective successors or permitted assigns, and it is not the intention of the parties hereto to confer third-party
beneficiary rights upon any other person or entity.
(h)
Waiver. Any delay or omission by a party in exercising its rights under this Agreement, or failure to insist upon strict compliance
with any term, covenant, or condition of this Agreement, will not be deemed a waiver of such term, covenant, condition or right, nor
will any waiver or relinquishment of any right or power under this Agreement at any time or times be deemed a waiver or relinquishment
of such right or power at any other time or times. No waiver will be effective unless it is expressly set forth in a written instrument
executed by the waiving party and any such waiver will have no effect except in the specific instance in which it is given.
(i)
No Strict Construction. No rule of strict construction will be applied against the Company in the interpretation of any of the
terms of this Agreement.
(j)
Ownership Rights. You will not have any distribution, voting or other rights of equity holder(s) of the Company by reason of this
Agreement.
(k)
No Employment Contract. You understand and acknowledge that this Agreement does not constitute a contract of employment and does
not establish or imply that your employment will continue for any period of time. Except as otherwise may be set forth in any written
employment agreement between you and the Company, you remain an employee at-will such that either you or the Company may terminate your
employment at any time, with or without cause or prior notice.
(l)
Survival. Provisions of this Agreement which by their nature are intended to survive termination or expiration of this Agreement
will survive any termination or expiration of this Agreement.
(m)
Governing Law. All matters arising out of, or relating to, this Agreement, including, without limitation, its validity, interpretation,
construction, performance and enforcement shall be governed by the laws of the state of California, determined without regard to its
conflicts of law principles.
(n)
JURY TRIAL WAIVER. TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, EACH OF THE PARTIES HERETO IRREVOCABLY WAIVES ALL RIGHT
OF TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM RELATING TO, ARISING OUT OF, OR IN CONNECTION WITH, THIS AGREEMENT, OR ANY
MATTER ARISING HEREUNDER. SUCH WAIVER IS A MATERIAL INDUCEMENT TO THE COMPANY’S ENTERING INTO THIS AGREEMENT.
(o)
Counterpart; Electronic Signatures. This Agreement may be executed in counterparts, all of which shall together constitute an
effective agreement. A facsimile or other electronic transmission of signatures to this Agreement shall be binding on the parties hereto.
(Signature
page follows.)
The
Company believes that this Agreement provides you with financial incentives to remain employed with the Company and committed to the
Company’s success. Please indicate your acceptance by signing below and returning it to me by May 26, 2023.
Sincerely
yours,
Guardion
Health Services, Inc.
By: |
/s/
Bret Scholtes |
|
Name: |
Bret
Scholtes |
|
Title: |
Member
of the Board of Directors |
|
I
agree to the terms and conditions set forth in this Agreement:
/s/
Katherine J. Cox |
|
May
21, 2023 |
Print
name: |
|
Date |
Signature
Page to Retention Agreement
v3.23.2
Cover
|
Jul. 25, 2023 |
Cover [Abstract] |
|
Document Type |
8-K
|
Amendment Flag |
false
|
Document Period End Date |
Jul. 25, 2023
|
Entity File Number |
001-38861
|
Entity Registrant Name |
GUARDION
HEALTH SCIENCES, INC.
|
Entity Central Index Key |
0001642375
|
Entity Tax Identification Number |
47-4428421
|
Entity Incorporation, State or Country Code |
DE
|
Entity Address, Address Line One |
2925
Richmond Avenue
|
Entity Address, Address Line Two |
Suite 1200
|
Entity Address, City or Town |
Houston
|
Entity Address, State or Province |
TX
|
Entity Address, Postal Zip Code |
77098
|
City Area Code |
(800)
|
Local Phone Number |
873-5141
|
Written Communications |
false
|
Soliciting Material |
false
|
Pre-commencement Tender Offer |
false
|
Pre-commencement Issuer Tender Offer |
false
|
Title of 12(b) Security |
Common
Stock, par value $0.001 per share
|
Trading Symbol |
GHSI
|
Security Exchange Name |
NASDAQ
|
Entity Emerging Growth Company |
true
|
Elected Not To Use the Extended Transition Period |
false
|
X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
+ Details
Name: |
dei_AmendmentFlag |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
+ References
+ Details
Name: |
dei_DocumentPeriodEndDate |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:dateItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
+ Details
Name: |
dei_DocumentType |
Namespace Prefix: |
dei_ |
Data Type: |
dei:submissionTypeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
+ References
+ Details
Name: |
dei_EntityAddressAddressLine1 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionAddress Line 2 such as Street or Suite number
+ References
+ Details
Name: |
dei_EntityAddressAddressLine2 |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- Definition
+ References
+ Details
Name: |
dei_EntityAddressCityOrTown |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCode for the postal or zip code
+ References
+ Details
Name: |
dei_EntityAddressPostalZipCode |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the state or province.
+ References
+ Details
Name: |
dei_EntityAddressStateOrProvince |
Namespace Prefix: |
dei_ |
Data Type: |
dei:stateOrProvinceItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityCentralIndexKey |
Namespace Prefix: |
dei_ |
Data Type: |
dei:centralIndexKeyItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionIndicate if registrant meets the emerging growth company criteria.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityEmergingGrowthCompany |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
+ Details
Name: |
dei_EntityFileNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:fileNumberItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
+ References
+ Details
Name: |
dei_EntityIncorporationStateCountryCode |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarStateCountryItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityRegistrantName |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2
+ Details
Name: |
dei_EntityTaxIdentificationNumber |
Namespace Prefix: |
dei_ |
Data Type: |
dei:employerIdItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionLocal phone number for entity.
+ References
+ Details
Name: |
dei_LocalPhoneNumber |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:normalizedStringItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 13e -Subsection 4c
+ Details
Name: |
dei_PreCommencementIssuerTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 14d -Subsection 2b
+ Details
Name: |
dei_PreCommencementTenderOffer |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTitle of a 12(b) registered security.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b
+ Details
Name: |
dei_Security12bTitle |
Namespace Prefix: |
dei_ |
Data Type: |
dei:securityTitleItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionName of the Exchange on which a security is registered.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1
+ Details
Name: |
dei_SecurityExchangeName |
Namespace Prefix: |
dei_ |
Data Type: |
dei:edgarExchangeCodeItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Section 14a -Number 240 -Subsection 12
+ Details
Name: |
dei_SolicitingMaterial |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
+ References
+ Details
Name: |
dei_TradingSymbol |
Namespace Prefix: |
dei_ |
Data Type: |
dei:tradingSymbolItemType |
Balance Type: |
na |
Period Type: |
duration |
|
X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.
+ ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Securities Act -Number 230 -Section 425
+ Details
Name: |
dei_WrittenCommunications |
Namespace Prefix: |
dei_ |
Data Type: |
xbrli:booleanItemType |
Balance Type: |
na |
Period Type: |
duration |
|
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Jun 2024 to Jul 2024
Guardion Health Sciences (NASDAQ:GHSI)
Historical Stock Chart
From Jul 2023 to Jul 2024